4880.T
CellSource Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 331.00
−0.30%Sep 8, 2026, 06:30 UTC
CellSource reported Q3 FY2026 cumulative ordinary profit of 174 million yen, up 37.0% year-on-year, and revised its full-year ordinary profit forecast upward from a 210 million yen loss to a 76 million yen profit, while revising its full-year net loss forecast downward from 107 million yen to 124 million yen.
Aug 31, 2026, 11:00 UTC
CellSource and Solaris Bio jointly developed freeze-drying technology for extracellular vesicles including exosomes.
Source: